Compared side by side
Semaglutide vs dulaglutide: how they differ
The short answer
Both are weekly GLP-1 receptor agonists, built differently: semaglutide mimics the gut hormone GLP-1 and lasts about a week, and dulaglutide is a fusion protein, two GLP-1 analogue chains joined to an antibody fragment, that lasts about 5 days. Semaglutide is FDA-approved for type 2 diabetes and weight management, as Ozempic and Wegovy; dulaglutide (Trulicity) is approved for type 2 diabetes and to lower cardiovascular events, and not for weight management. Semaglutide averaged about 15% weight loss at 68 weeks in its main trial, while dulaglutide’s effect on weight was about 1 to 5 kg in its diabetes trials.
Side by side
| Compared | Semaglutide | Dulaglutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Ozempic, Wegovy | Trulicity, LY2189265, Dula |
| What it is | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. | A weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens. |
| How it works | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. | GLP-1 receptor agonist made as a fusion protein: two GLP-1 analogue chains, 90% the same as human GLP-1, joined to the Fc fragment of a modified IgG4 antibody (about 63 kDa). It releases insulin when glucose is high, lowers glucagon and slows stomach emptying. Its large Fc-fusion design slows its clearance, to a half-life of about 5 days, which makes it a weekly shot. FDA-approved in 2014 for type 2 diabetes (adults, and children 10 and older) and to lower major cardiovascular events in adults with type 2 diabetes and heart disease or its risk factors; it is not approved for weight management. |
| Commonly reported | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. | Steadier glucose readings and, for some, a smaller appetite, with nausea or loose stools mostly in the first weeks and after a step-up. FDA-approved since 2014, with more than a decade of use behind it. |
| Studied range | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. | FDA label: 0.75–4.5 mg, starting dose 0.75 mg. |
| How often | Weekly SubQ | Weekly |
| Half-life | ~1 week (FDA label) | ~5 days (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. | FDA-approved for ongoing use; its heart-outcomes trial followed people for a median of 5.4 years. The 3 and 4.5 mg steps are optional, for more glucose control. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue |
- Category
- SemaglutideMetabolic & GLP-1
- DulaglutideMetabolic & GLP-1
- Also known as
- SemaglutideOzempic, Wegovy
- DulaglutideTrulicity, LY2189265, Dula
- What it is
- SemaglutideA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
- DulaglutideA weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens.
- How it works
- SemaglutideGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
- DulaglutideGLP-1 receptor agonist made as a fusion protein: two GLP-1 analogue chains, 90% the same as human GLP-1, joined to the Fc fragment of a modified IgG4 antibody (about 63 kDa). It releases insulin when glucose is high, lowers glucagon and slows stomach emptying. Its large Fc-fusion design slows its clearance, to a half-life of about 5 days, which makes it a weekly shot. FDA-approved in 2014 for type 2 diabetes (adults, and children 10 and older) and to lower major cardiovascular events in adults with type 2 diabetes and heart disease or its risk factors; it is not approved for weight management.
- Commonly reported
- SemaglutideThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
- DulaglutideSteadier glucose readings and, for some, a smaller appetite, with nausea or loose stools mostly in the first weeks and after a step-up. FDA-approved since 2014, with more than a decade of use behind it.
- Studied range
- SemaglutideFDA label: 0.25–2.4 mg, starting dose 0.25 mg.
- DulaglutideFDA label: 0.75–4.5 mg, starting dose 0.75 mg.
- How often
- SemaglutideWeekly SubQ
- DulaglutideWeekly
- Half-life
- Semaglutide~1 week (FDA label)
- Dulaglutide~5 days (FDA label)
- Route
- SemaglutideSubQ injection
- DulaglutideSubQ injection
- Typical run
- SemaglutideFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
- DulaglutideFDA-approved for ongoing use; its heart-outcomes trial followed people for a median of 5.4 years. The 3 and 4.5 mg steps are optional, for more glucose control.
- Evidence
- SemaglutideEstablished: clinical trials or FDA-approved use exists
- DulaglutideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- SemaglutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk
- DulaglutideNausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Semaglutide
- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline
Dulaglutide
- Day 1–28 · 0.75 mg The 0.75 mg start
- Day 29–364 · 1.5 mg 1.5 mg, the dose of its heart trial
- Day 57–364 · 3 mg 3 mg, a step for more glucose control
- Day 85–364 · 4.5 mg 4.5 mg, the top dose
- Day 365+ A long-term medicine, not a course
Questions people ask
How long do semaglutide and dulaglutide last?
The half-life of semaglutide is ~1 week (FDA label). The half-life of dulaglutide is ~5 days (FDA label).
How often are semaglutide and dulaglutide taken?
Semaglutide: weekly SubQ. Route: SubQ injection. Dulaglutide: weekly. Route: SubQ injection.
How are semaglutide and dulaglutide dosed in research?
The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The FDA label range for dulaglutide is 0.75–4.5 mg, with a 0.75 mg starting dose.
What are the common side effects of semaglutide and dulaglutide?
For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For dulaglutide: nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue.